Pleo Sanuvis
FDA Label NDC 60681-6303

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Sanum Kehlbeck Gmbh & Co. Kg for the product Pleo Sanuvis (NDC 60681-6303). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding otc - purpose, indications, inactive ingredient, tamper evident, dosage, warning, otc - keep out of reach of children, principal display panel - 80 tablet carton, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Otc - Purpose

Homeopathic Digestive Aid Lactic Acid

80 Tablets

Indications

Digestive aid for pre and post operative support.

Inactive Ingredient

One tablet contains 50 mg Acidum L(+)-lacticum 4X, 50 mg Acidum L(+)-lacticum 6X , 50 mg Acidum L(+)-lacticum 12X, 50 mg Acidum L(+)-lacticum 30X, 50 mg Acidum L(+)-lacticum 200X in a base of lactose, potato starch, magnesium stearate.

Tamper Evident

Do not use this product if imprinted inner blister pack is broken.

Dosage

1-3x daily 1-2 tablet.

Warning

If symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before using this product.

Otc - Keep Out Of Reach Of Children

Keep this and all other medications out of the reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Principal Display Panel - 80 Tablet Carton

Pleo® Sanuvis
TABLETS

Homeopathic
Digestive Aid
Lactic Acid

The original
SANUM®
brand remedies

Indications:
Digestive aid for
pre and post
operative support.

80 TABLETS

Principal Display Panel (80 Tablet Carton)

Principal Display Panel (80 Tablet Carton)

* Please review the disclaimer below.